CP-742,033 + fenofibrate

CP-742,033 + fenofibrate is an experimental combination of two drugs: CP-742,033, a compound under investigation by Pfizer for the treatment of obesity, and fenofibrate, a well-established peroxisome proliferator-activated receptor alpha (PPARα) agonist used for lipid lowering in conditions such as hypercholesterolemia and hypertriglyceridemia. The mechanism of CP-742,033 is not publicly detailed, but its primary indication is obesity. The combination was investigated for its safety, toleration, and biomarker efficacy in obese adults but the phase 1 clinical trial was withdrawn prior to completion[1][5]. Fenofibrate acts by activating PPARα, which modulates lipid metabolism and reduces triglycerides while increasing HDL cholesterol[3][4].